Celgene (CELG)
This biotech is growing at double-digit rates, just settled a major patent litigation suit, and 16 of its 19 analysts rate the stock a ‘buy’ or ‘strong buy’.
Celgene (CELG) From Wong’s BioTech Stock Report
Celgene’s (CELG) core business has three franchises, hematologic malignancy, solid and...
Read More